CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...

Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene ...

Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy ...

Bristol Myers Squibb BMY recently obtained FDA approval for the label expansion of Breyanzi (lisocabtagene maraleucel) for ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...

Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results.

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. Doctors harvest the patient’s T cells, the soldiers of the immune ...

The U.S. Food and Drug Administration has approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first ...

(Yicai) Dec. 5 -- China is becoming a global center for chimeric antigen receptor-T cell therapy, which re-engineers a ...